November 6, 2015

The Master Class XVI • 2015

Disclaimer

The recommendations provided by the authors were presented on November 6, 2015, at the annual national meeting of Mentoring in IBD: The Master Class in Toronto, Ontario. The opinions and recommendations do not necessarily accurately reflect the current state of affairs or the current advice the authors may choose to provide in the same circumstances. Please refer to the current guidelines or the Canadian Association of Gastroenterology for up-to-date treatment options.

Learning Objectives

The educational objective of Mentoring in IBD is to increase awareness of current developments and best practices in inflammatory bowel disease (IBD) management, promote collaboration among Canadian gastroenterologists, and optimize treatment of IBD.

Participants in this program will be able to:

  • Assess the state of mental health in IBD patients and develop pragmatic approaches to address and manage mental health issues
  • Determine when and how to switch from one biologic agent to another to optimize management of IBD
  • Appraise the efficacy of dietary therapies in IBD
  • Examine the rules of stopping biologics in IBD therapy from the perspectives of the North American and European environments
  • Evaluate two clinical trials that will change post-operative practice in IBD
  • Survey current IBD literature

 

Mental Health and IBD

Presented by Rebecca Anglin

Workshop Case

Abstract and References

State-of-the-art Plenary Presentation

Optimizing Management in IBD: Switching Biologics

Presented by Edward V. Loftus Jr

Workshop Case

Abstract and References

State-of-the-art Plenary Presentation

Vitamin D in IBD

Presented by Khursheed Jeejeebhoy

Abstract and References

State-of-the-art Plenary Presentation

The Rules of Stopping Biologics: A European Perspective

Presented by Alessandro Armuzzi

Workshop Case

Abstract and References

State-of-the-art Plenary Presentation

The Rules of Stopping Biologics: A North American Perspective

Presented by Brian Feagan

Workshop Case

Abstract and References

State-of-the-art Plenary Presentation

PREVENT Study Data: Infliximab in the postoperative Crohn's disease environment

Presented by A. Hillary Steinhart

Abstract and References

State-of-the-art Plenary Presentation

POCER Study Data: Adalimumab in the postoperative Crohn's disease environment

Presented by Geoffrey Nguyen

Abstract and References

State-of-the-art Plenary Presentation